Latest Commercialisation Strategies News

Page 4 of 15
Tartana Minerals has kicked off an ambitious drilling program at its Tartana Copper Project aiming to more than double its contained copper resource beyond the existing open pit. Early drilling progress and operational upgrades signal a push toward expanding production and resource depth.
Maxwell Dee
Maxwell Dee
4 June 2026
Terragen Holdings secures a landmark supply agreement for its probiotic and biostimulant products with Ravensworth Feedlot, alongside a $2.8 million funded trial at Mort & Co’s Grassdale feedlot to validate its probiotic’s impact on cattle performance.
Ada Torres
Ada Torres
28 May 2026
NoviqTech's Coralia has kicked off a comprehensive trial converting invasive Chinese Apple trees into biochar at its Great Barrier Reef project, aiming to validate carbon removal methods and support institutional partnerships.
Maxwell Dee
Maxwell Dee
28 May 2026
Cleo Diagnostics has laid out a clear U.S. reimbursement pathway for its ovarian cancer test, leveraging an existing CPT code to enable early market entry and data collection ahead of FDA clearance.
Ada Torres
Ada Torres
20 May 2026
Bayan Mining and US Critical Materials have signed a non-binding MoU to develop rare-earth processing technologies licensed from the Colorado School of Mines, targeting high-grade mineralisation at the Sheep Creek Project in Montana. The collaboration aims to support a US-based rare earth supply chain with potential strategic investment on the horizon.
Maxwell Dee
Maxwell Dee
14 May 2026
Nexsen has secured a strategic partnership with GHK Hospital Limited in Hong Kong, marking a significant step in validating and commercialising its rapid point-of-care diagnostics across North Asia.
Ada Torres
Ada Torres
13 May 2026
Forte Energy has rapidly expanded its oil and gas exploration portfolio in Alaska’s National Petroleum Reserve, acquiring over 156,000 acres including the billion-barrel Harrier Prospect and adjacent leases to Umiat Oil Field, while securing significant cost savings through lease fee suspensions.
Maxwell Dee
Maxwell Dee
30 Apr 2026
Rhythm Biosciences marked a pivotal shift from development to commercial diagnostics in Q3 FY26, recording its first ColoSTAT® clinical sale and initiating NHS England evaluation while expanding geneType™ partnerships across Asia and Australia.
Ada Torres
Ada Torres
30 Apr 2026
Orthocell has initiated commercial sales of its Remplir nerve repair device in Canada, leveraging a distributor-led model to penetrate a US$75 million market and setting the stage for broader North American expansion.
Ada Torres
Ada Torres
30 Apr 2026
xReality Group delivered a standout Q3 FY26 with a 62% jump in cash receipts and a new Mixed Reality sale to the US Department of Defense, underpinning its growing Operator XR platform.
Sophie Babbage
Sophie Babbage
30 Apr 2026
Epiminder has ramped up enrolment in its DETECT study, contracting 18 US medical centres and maintaining a robust $83.8 million cash position to fund its Minder device commercialisation through 2028.
Ada Torres
Ada Torres
30 Apr 2026
Biome Australia has taken a significant step in its innovation journey by filing a patent for its next generation probiotic strain BMB18, with a clinical trial set to begin in Q4 FY26 in partnership with La Trobe University.
Ada Torres
Ada Torres
27 Apr 2026

Browse the archive

Full archive